Big Volume and Gain for Enterologics (OTC:ELGO)

Naples, FL 5/20/2011 (PennyPayDay) -- Enterologics, Inc. (OTC:ELGO) announced yesterday, in a press release, that it has teamed with Universal Stabilization Technologies, Inc. ("UST") to produce a new, shelf-stable formulation of a probiotic based on UST's proprietary technology. Enterologics is funding the development program, in which UST will optimize a pharmaceutical-grade probiotic dosage form with extended shelf-life and viability at ambient temperatures.

"UST's vitrification technology represents a significant advance for preserving the viability of probiotics in a convenient oral dosage form," said Enterologics' president, Bob Hoerr. "We believe that this proprietary, shelf-stable dosage form will enable us to meet a key goal in our commercialization program to develop probiotic products as approved biologic drugs for gastrointestinal diseases."

Victor Bronshtein, Ph.D., president and founder of UST, stated, "Based on our research, our proprietary dosage format should enable probiotics to meet ambient (from -20°C to + 37°C) temperature shelf-life standards for a pharmaceutical product. Probiotics that are proven thermostable will ensure the confidence of patients and prescribing physicians that a product provides the number of live probiotic bacteria listed on the label, not merely at the time of manufacture, but at the time of use. Demonstrated probiotic potency at the time of use is critical for defining an accurate therapeutic dose for targeted diseases. This is not the case for many probiotic products now marketed through consumer channels."

In January, UST granted Enterologics a right of first refusal for 16 months to enter into a definitive, exclusive, royalty-bearing, worldwide license agreement for UST's intellectual property in the field of preservation or stabilization of Escherichia coli ("E. coli") probiotic bacteria. As planned, Enterologics has initiated funding for a development project to show that UST's stabilization technology can produce a thermostable, commercially viable formulation of an E. coli probiotic that satisfies the Company's specifications.

Enterologics is a biotechnology company that is developing probiotics as biologic drugs for specific gastrointestinal disease indications.

Distributed by IntelBuilder Social Media Platform